Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed by Metronomic Therapy With Temozolomide for Newly Diagnosed Malignant High Grade Glioma

NCT00548938 is registered in ClinicalTrials.gov with Methodist Healthcare - Memphis as lead sponsor.

NCT NCT00548938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00548938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed by Metronomic Therapy With Temozolomide for Newly Diagnosed Malignant High Grade Glioma
Lead sponsor
Methodist Healthcare - Memphis
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2007
Completion date
October 31, 2010
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, high-grade glioma